Stenoparib Receives FDA Fast Track Designation in Advanced Ovarian Cancer
Written by
Cancer Network
Published
0
comments
0
min
The novel treatment was evaluated in a phase 2 trial and saw a clinical benefit in patients with advanced ovarian cancer.